BBT-059
Intestinal injury (e.g., from radiation)
PreclinicalActive
Key Facts
Indication
Intestinal injury (e.g., from radiation)
Phase
Preclinical
Status
Active
Company
About Bolder Biotechnology
Bolder Biotechnology is a private, preclinical-stage biotech firm leveraging its protein engineering platform to design next-generation cytokine therapeutics. The company's approach centers on creating modified proteins with extended half-lives and enhanced activity profiles, targeting significant markets in oncology, autoimmune disorders, and hematology. As a long-standing entity founded in 2001, it has sustained research and development efforts, though it operates as a pre-revenue company reliant on private investment and partnerships. Its success hinges on advancing its lead candidates into clinical trials and securing strategic collaborations to fund development.
View full company profile